重症患者游离丙戊酸浓度评估
这项回顾性多中心队列研究纳入2个学术医疗中心256例在ICU同时采集游离和总丙戊酸浓度的成人患者,评估游离丙戊酸浓度及其相关因素。结果显示总丙戊酸浓度中位数53 µg/mL,游离浓度12 µg/mL,游离分数23.6%,游离与总浓度治疗不一致占70%。多因素分析中,总丙戊酸浓度每升高5 µg/mL,游离浓度增加1.72 µg/mL(95% CI 1.48-1.96);血清白蛋白每降低1 g/dL,游离浓度增加4.60 µg/mL(95% CI 2.71-6.49)。游离丙戊酸浓度与不良效应无关联。作者认为基于总浓度的临床决策对许多ICU患者可能不正确,需前瞻性对照研究确认。
要点
- ICU患者游离与总丙戊酸浓度治疗不一致发生率为70%。
- 总丙戊酸浓度每升高5 µg/mL,游离浓度增加1.72 µg/mL(95% CI 1.48-1.96)。
- 血清白蛋白每降低1 g/dL,游离丙戊酸浓度增加4.60 µg/mL(95% CI 2.71-6.49)。
- 游离丙戊酸浓度与不良效应无关联。
- 作者认为基于总丙戊酸浓度的临床决策对许多ICU患者可能不正确。
适用人群与场景
- 年龄大于或等于18岁、在ICU同时采集游离和总丙戊酸浓度的患者。
研究设计与关键结果
- 研究类型:回顾性多中心队列研究,2个学术医疗中心,256例患者。
- 人群特征:中位年龄56岁(42-70),65%为男性。
- 浓度结果:总丙戊酸浓度中位数53 µg/mL(38-70 µg/mL),游离丙戊酸浓度12 µg/mL(7-20 µg/mL),游离分数23.6%(17.0-33.9%)。
- 游离与总丙戊酸浓度治疗不一致发生率为70%。
- 多因素分析:总丙戊酸浓度每升高5 µg/mL,游离浓度增加1.72 µg/mL(95% CI 1.48-1.96);血清白蛋白每降低1 g/dL,游离浓度增加4.60 µg/mL(95% CI 2.71-6.49)。
- 游离丙戊酸浓度与不良效应无关联。
证据类型、等级与局限
- 证据类型:回顾性多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为基于总丙戊酸浓度的临床决策对许多ICU患者可能不正确。
- 作者认为需前瞻性对照研究确认这些发现及其临床相关性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Protein binding of valproate is variable in ICU patients, and the total valproate concentration does not predict the free valproate concentration, even when correcting for albumin. We sought to quantify valproate free concentration among ICU patients, identify risk factors associated with an increasing free valproate concentration, and evaluate the association between free valproate concentration with potential adverse drug effect.
DESIGN: Retrospective multicenter cohort study.
SETTING: Two academic medical centers.
PATIENTS: Patients greater than or equal to 18 years of age with concomitant free and total valproate concentrations collected in the ICU.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Two-hundred fifty-six patients were included in the study, with a median age of 56 years (42-70) and 65% of patients were male. The median total valproate concentration was 53 µg/mL (38-70 µg/mL), the free valproate concentration was 12 µg/mL (7-20 µg/mL), and the free fraction was 23.6% (17.0-33.9%). Therapeutic discordance between the free and total valproate concentration occurred in 70% of patients. On multivariable analysis, increased free valproate concentration was associated with higher total valproate concentration (per 5 µg/mL increase, increase 1.72 µg/mL, 95% CI, 1.48-1.96) and lower serum albumin (per 1 g/dL decrease, increase 4.60 µg/mL, 95% CI, 2.71-6.49). There was no association between free valproate concentration and adverse effects.
CONCLUSIONS: The valproate total and free concentration was discordant in the majority of patients (70%). Increased valproate free concentration was associated with hypoalbuminemia and total valproate concentration. Clinical decisions based on total valproate concentration may be incorrect for many ICU patients. Prospective, controlled studies are needed to confirm these findings and their clinical relevance.
参考来源
- Brown CS, Liu J, Riker RR, et al. Evaluation of Free Valproate Concentration in Critically Ill Patients. Crit Care Explor. 2022. PMID: 37942235. doi:10.1097/CCE.0000000000000746
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。